Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer
24/02/2026 14:08
Feb 24 (Reuters) - Alpha Tau Medical Ltd DRTS.O: ALPHA TAU MEDICAL RECEIVES JAPANESE MARKETING APPROVAL FOR ALPHA DART® IN UNRESECTABLE LOCALLY ADVANCED OR LOCALLY RECURRENT HEAD AND NECK CANCER Source text: ID:nGNX5dzw1 Further company coverage: DRTS.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer